Currently out of the existing stock ratings of Thomas Wei, 3 are a SELL (13.64%), 2 are a HOLD (9.09%), 17 are a BUY (77.27%).

Thomas Wei

Work Performance Price Targets & Ratings Chart

Analyst Thomas Wei, carries an average stock price target met ratio of 81.82% that have a potential upside of 43.41% achieved within 354 days. Previously, Thomas Wei worked at JEFFERIES.

Thomas Wei’s has documented 52 price targets and ratings displayed on 12 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on STML, Stemline Therapeutics at 21-Apr-2015.

Wall Street Analyst Thomas Wei

Analyst best performing recommendations are on ACAD (ACADIA PHARMACEUTICALS).
The best stock recommendation documented was for ACAD (ACADIA PHARMACEUTICALS) at 5/6/2013. The price target of $18 was fulfilled within 35 days with a profit of $5.82 (47.78%) receiving and performance score of 13.65.

Average potential price target upside

of $35.9 (14.01%) on BIIB (BIOGEN).
of $21.57 (29.76%) on CELG (CELGENE).
of $19.16 (38.06%) on INCY (YTE).

AMRN Amarin PLC BIIB Biogen DVAX Dynavax Technologies INCY yte VVUS VIVUS ACAD ACADIA Pharmaceuticals NBIX Neurocrine Biosciences STML Stemline Therapeutics ARNA Arena Pharmaceuticals ARWR Arrowhead Pharmaceuticals CELG Celgene MDGL Madrigal Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Paul Choi (GOLDMAN)